AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Sunday 15 November 2026
News from the 24 hours to Sunday morning, 15 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage leaned positive on US approvals for two treatments and progress toward EU clearance for a hypertension drug. This was partly offset by reports of 600 US job cuts under a cost-saving plan, while AstraZeneca's SAP cloud deal drew mild positive mentions.
What drove it
- FDA approvals
- US job cuts
- SAP cloud deal
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
| Sat 14 Nov | +5.5 | 39 |
| Sun 15 Nov | +7.5 | 9 |
| Mon 16 Nov | +4.5 | 6 |
5 stories · 9 headlines · strongest first
Pharma and healthcare on 15 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca signs cloud ERP deal with SAP +3.34 headlines today · Articles say AstraZeneca signed on to a large SAP cloud move, alongside a JPMorgan SAP target increase and SAP buyback. | ||
| +4.2 | AZ named as a client moving to SAP cloud; mainly an SAP story. | |
| +4.2 | AZ commits to a large cloud migration; focus is on SAP. | |
| +2.5 | AZ cloud deal mentioned, but story centres on SAP. | |
| +2.5 | AZ cloud deal is a minor part of an SAP story. | |
| AstraZeneca reduces its US sales workforce by 600 positions −2.72 headlines today · 16 in all, since 14 November · Reports cover the 600 US job cuts within a $1.5bn savings plan. | ||
| −3.3 | Job losses in the US, though part of a cost-saving programme. | |
| −2.5 | Share-focused look at US sales reductions and cost drive. | |
| FDA approves AstraZeneca's Klygefa for myasthenia gravis +10.01 headline today · The FDA approved Klygefa for generalised myasthenia gravis. | ||
| +10.0 | US regulator clears new treatment for a rare muscle condition. | |
| FDA approves Imfinzi regimen for bladder cancer +10.01 headline today · 8 in all, since 14 November · Imfinzi combined with enfortumab vedotin has received FDA approval in cases of muscle-invasive bladder cancer. | ||
| +10.0 | US clearance widens use of Imfinzi in bladder cancer. | |
| EU committee recommends AstraZeneca's Baxfendy for hypertension +8.91 headline today · 8 in all, since 14 November · Baxfendy, a hypertension treatment that is the first of its type, has taken a step towards authorisation in the EU. | ||
| +9.2 | Novel hypertension drug advancing toward European regulatory clearance. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.